The Molecular Tumor Board of the COP-U Mayor (MTB-COP U Mayor) analysed these cases to inform future clinical decisions regarding the treatment of patients with IDH mutations, based on the findings observed in Chilean cancer patients cohorts. Here, IDH2 is linked to cancer.